This study is to find out if ranibizumab is safe and effective compared to laser therapy in preterm babies with ROP, a condition of abnormal blood vessel (arteries and veins) development in the eyes

Update l'année dernière
Reference: EUCTR2014-003041-10

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To demonstrate that intravitreal ranibizumab 0.2 mg has superior efficacy to laser therapy in the treatment of ROP as measured by the absence of active ROP and absence of unfavorable structural outcomes in both eyes 24 weeks after starting investigational treatment.


Inclusion criteria

  • Retinopathy of prematurity (ROP)